Lilly announced on their conference call today that the triple agonist (GLP-1, GIP, Glucagon) retatrutide achieved 22-24% weight loss at 48 weeks with a similar tolerability profile to tirzepatide. They are moving forward with phase 3 for obesity.
— Todd Skelton (@xKloc) December 13, 2022
The Fat Celebration movement is probably in intense mourning. But very good news for everyone else.